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http://dx.doi.org/10.1016/j.ccell.2015.09.008SUMMARYWhile recombinant humanerythropoietin (rhEpo) hasbeenwidely used to treat anemia in cancerpatients, con-
cerns about its adverse effects on patient survival have emerged. A lack of correlation between expression of
thecanonical EpoRand rhEpo’seffectsoncancer cells promptedus toconsider theexistenceof analternative
Epo receptor. Here,we identifiedEphB4as anEpo receptor that triggers downstreamsignaling via STAT3and
promotes rhEpo-induced tumor growth and progression. In human ovarian and breast cancer samples,
expression of EphB4 rather than the canonical EpoR correlated with decreased disease-specific survival in
rhEpo-treated patients. These results identify EphB4 as a critical mediator of erythropoietin-induced tumor
progression and further provide clinically significant dimension to the biology of erythropoietin.INTRODUCTION
Erythropoiesis-stimulating agents (ESAs), such as recombinant
human epoetin (rhEpo) and darbepoetin, are recombinant glyco-Significance
Themechanisms underlying the adverse effects of Epo-stimula
well understood. Here, we identified EphB4 as an alternative Ep
also showed that rhEpo-mediated tumor growth can be abrog
human ovarian and breast cancer samples revealed that Eph
outcome in Epo-treated patients. Overall, we present converg
EphB4 is a critical mediator of Epo-induced cancer growth. Our
sion to the biology of erythropoietin.
610 Cancer Cell 28, 610–622, November 9, 2015 ª2015 Elsevier Inc.sylated analogs of erythropoietin (Epo) that have been used to
relieve chemotherapy-induced anemia in cancer patients
(Glaspy, 2009a; Sytkowski, 2007). Epo is a pleiotropic cytokine
that regulates erythropoiesis, angiogenesis, cytoprotection,ting agents on the reduced survival of cancer patients are not
o receptor, which triggers Src/Stat3 signaling via EphB4.We
ated by targeting EphB4 in vivo. In our study, evaluation of
B4, but not the canonical EpoR, correlated with a clinical
ing evidence from in vitro, in vivo, and clinical studies that
study provides an important and clinically significant dimen-
and proliferation (Foley, 2008; Glaspy, 2009b). Alarmingly, a
growing number of studies have demonstrated that ESA-based
treatment can compromise the overall survival of cancer patients
(Crouch and DeSantis, 2009; Kumar et al., 2012; To´va´ri et al.,
2008; Wang et al., 2011), raising the possibility of growth-stimu-
latory effects on cancer cells via the canonical Epo receptor
(EpoR) (Aapro et al., 2012; Chateauvieux et al., 2011; Hedley
et al., 2011; McKinney and Arcasoy, 2011; Rathod and Sala-
hudeen, 2011). However, EpoR expression on cancer cells has
largely failed to explain the effects of rhEpo on tumor growth.
For example, rhEpo can affect proliferative and survival re-
sponses in cancer cells without EpoR expression (Okazaki
et al., 2008), while failing to induce proliferation in EpoR-positive
tumor cells (Belda-Iniesta et al., 2007). Other explanations (e.g.,
EpoR variants) have also been inadequate in explaining the ef-
fects of rhEpo on tumor growth (Foley, 2008).
Evidence from other therapeutic areas has also suggested
the existence of an alternative Epo receptor. For example, carba-
mylated Epo (cEpo) does not stimulate erythropoiesis, yet it pre-
vents tissue injury in response to hypoxic conditions (Chen et al.,
2009; Leist et al., 2004; Zamora et al., 2005) in an EpoR-indepen-
dentmanner (Leist etal., 2004).Suchobservations,combinedwith
a lackof a convincingmolecular explanationunderlying theeffects
of rhEpooncancer growth, promptedus to consider the existence
of an alternative Epo receptor. Using a hypothesis-driven
in silico strategy, we further explored ephrin-type B receptor 4
(EphB4) as an alternative candidate Epo receptor that accounts
for many of the growth-stimulatory effects of rhEpo in tumors.
RESULTS
In Silico Identification of an Alternative Candidate
Epo Receptor
Epo-mediated tissue protection under conditions such as
hypoxia occurs in an EpoR-independent manner (Brines and
Cerami, 2012; Brines et al., 2008). We reasoned that while
expression of an alternative Epo receptor may mediate potential
therapeutic responses to Epo under low-oxygen conditions (e.g.,
after ischemic stroke), expression of this same receptor on tumor
cells could provide themwith a survival advantage in response to
Epo treatment. Such an ‘‘off-target’’ mechanism could have
serious implications for cancer patient survival andmight explain
the emerging clinical evidence supporting such an effect. To
identify this elusive receptor, we analyzed the membrane-bound
portion of the proteome for candidate receptors possessing
structural, regulatory, and functional features consistent with
Epo binding, response to hypoxic conditions, and tumorigenic
signaling. Employing a combination of bioinformatics and text-
mining approaches, we identified EphB4, IL6rb, Tie1, Tf, and
Ghr as potential candidates. While EphB4 and IL6rb showed
evidence of involvement in angiogenesis and erythropoiesis,
analysis of the Epo genomic locus revealed that it is contiguous
to the EPHB4 gene, a phenomenon not uncommon to many
functionally interacting proteins (Figure S1A). Subsequent struc-
tural analyses identified potential Epo binding sites on EphB4,
leading us to select this molecule as our prime candidate for
an alternative Epo receptor (Figure 1A).
We initially assessed whether rhEpo binds to EphB4 using
fluorescence microscale thermophoresis (MST) and surfaceCaplasmon resonance (SPR). MST experiments with fluorophore-
labeled rhEpo demonstrated binding to EpoR with an apparent
dissociation constant (KD,app) of 28.0 ± 14.0 nM (Figure 1B)
and EphB4 with a KD,app value of 880.6 ± 128.6 nM; Figure 1C).
EphB4 and EphrinB2 bound with a KD,app value of 140.5 ±
28.3 nM (Figure 1D). The BSA control showed no binding to
EpoR or EphB4 (Figures S1B and S1C). SPR studies revealed
that rhEpo competes with EphrinB2 for EphB4 in a dose-depen-
dent manner (Figures 1E and 1F). Controls showed EphrinB2
binding to EphB4 and rhEpo binding to EpoR (Figures S1D and
S1E). A ligand with lower binding affinity can bind to its corre-
sponding receptor and exert biological functions (Figure S1F).
To test the specificity of rhEpo binding to EphB4, we also tested
several other Eph receptors. No binding was noted between
rhEpo and EphA2, EphA3 or EphB2 (Figures S1G–S1I); for con-
trols, we used EphrinA1 as the ligand for EphA2, EphrinB2 for
EphB2, and EphrinA2 for EphA3. The presence of rhEpo did
not interfere with the binding of these ligands to their corre-
sponding receptors (Figures S1J–S1L). Both rhEpo-alpha and
rhEpo-beta also bind to EphB4 (50 ng/ml) in the presence of
[I125] rhEpo (Figures S1M and S1N).
Next, we examined a panel of cell lines for EpoR, EphB4, and
EphrinB2 expression (Figures S1O–S1Q). EphrinB2 is present
in endothelial cells, both in vitro and in vivo, but no significant
increase in its expression was observed after rhEpo stimulation
(Figures S1R–S1U). The A2780 cells express both EpoR
and EphB4, but lack EphrinB2 (Figures S1O–S1Q) and IL6rb
(Figures S1V and S1W). To confirm specificity of the EpoR anti-
body, we ectopically expressed HA-tagged EpoR in A2780 cells
and detected EpoR expression using HA antibody (Figure S1X).
rhEpo Binds to EphB4
Next, we established stably transfected clones with small hairpin
RNA (shRNA) against EpoR (shEpoR), EphB4 (shEphB4), or both
in A2780 cells (Figures S2A–S2D). ShEpoR clone 3 and shEphB4
clone 1 were used for subsequent experiments. rhEpo compet-
itively inhibited [I125]rhEpo binding to A2780-shEpoR and A2780-
shEphB4 cells (Figure 2A); there was no binding of [I125]rhEpo to
A2780-shEpoR/shEphB4 cells (Figure 2B). To further examine
the potential for EphB4 binding to Epo, we also generated
EpoR/ mouse embryonic fibroblasts (MEFs) (EphB4 positive)
from EpoR/ mice and found that [I125]rhEpo can bind to these
cells (Figure 2C).
To further examine binding between Epo and EpoR or EphB4,
we ectopically expressed EpoR or EphB4 in EpoR/EphB4-null
Cos-1 cells. rhEpo competitively inhibited [I125]rhEpo binding to
both clones (Figure S2E; Table S2), and no binding was noted
inCos-1-EV (empty vector) cells. To test the specificity of shRNA,
additional clones were tested with similar results obtained
(Figure S2F). Similar binding patterns were also noted in MDA-
MB231 (Figure S2G) andMCF-7 breast cancer cells (Figure S2H).
Next, we designed several peptides from the EphB4 extracel-
lular domain based on potential interaction sites from the 3D
structures of EphB4:EphrinB2 and EpoR:Epo complexes (Fig-
ure S2I). In competitive binding assays with rhEpo and each pep-
tide (Figures 2D and S2J), only the EEL peptide (amino acids
43–58 of the EphB4 extracellular domain covers the C-D loop
[Chrencik et al., 2006a], a region involved in Ephrin-binding) in-
hibited the binding of [I125]-rhEpo to A2780-shEpoR cells.ncer Cell 28, 610–622, November 9, 2015 ª2015 Elsevier Inc. 611
Figure 1. Epo Binds to EphB4
(A) X-ray crystal structure of EphB4 (green), EphrinB2 (blue), and Epo (blue) -EpoR (green) complex. The C-D region, from which the inhibitory peptide has been
derived, is highlighted in red. E43, E44, and L45 are involved in EphrinB2 binding. Interactions between homology region with EpoR and ligand are shown in detail:
E43, E44, and L45 of EphB4 interact with K60, T114, and K116 of EphrinB2. The acidic residues in the apical position of the loop (E50, E51) are shown as well. The
A-B loop region homologous to the inhibitory peptide is highlighted in red. The interaction between K97 and R14 of Epo with the acidic residue located on the
apical loop of the EpoR homology region (E34) is also shown. E24, E25, and L26 of EpoR are homologous to residues E43, E44, and L45 of EphB4, which are
known to be involved in Ephrin ligand binding. Acidic residues are located in the loop in an apical position similar to the location of acidic residues in the A-B loop
region of the Epo receptor.
(B and C) Fluorescence microscale thermophoresis analysis of Epo binding to EpoR (B) or EphB4 (C).
(D) EphrinB2 binding to labeled EphB4.
(E) Surface competition assay (SCA) of Epo and EphrinB2 with a coated EphB4 receptor using the BIAcore instrument for detection of bound protein. Serial
dilutions of Epo were mixed with EphrinB2 and injected onto a CM5 chip, to which EphB4 was bound.
(F) Bound protein shown as response units (RU) at the end of association was plotted as a function of Epo concentration and fit with a three-parameter non-linear
regression using GraphPad Prism (v.5.0). Samples and a buffer blank were injected in duplicate. Mean ± SEM values are shown (n = 3).
See also Figure S1.Alignment of the N-terminal domains of EphB4 and EpoR indi-
cated that the EEL peptide contains several residues that are
identical or similar to residues in the A-B loop of EpoR, which
are involved in Epo binding (Syed et al., 1998). We designed spe-
cific plasmids encoding EphB4 with a mutation at the EphrinB2
binding domain. The mutation site corresponds to the amino
acids included in the EEL peptide: Ser46, Leu48, Glu50, Glu44,
and Tyr58 (Table S1) (Chrencik et al., 2006a, 2006b). The
Ser46-mutated site did not affect rhEpo binding, but mutations
in Leu48 blocked rhEpo binding (Figure S2K; Table S2). We612 Cancer Cell 28, 610–622, November 9, 2015 ª2015 Elsevier Inc.also mutated shared residues (Glu50 or Glu44, Tyr58) involved
in Epo binding in both EphB4 and EpoR; mutations on Glu44
or Glu50 (but not Tyr58) interrupted the binding of Epo to
EphB4 (Figure S2L; Table S2). Using proximity ligation assays,
we found that Epo and EphB4 interact directly in Cos-1/EpoR
and Cos-1/EphB4 cells (Figures 2E and 2F).
Next, we performed competitive binding studies in which
A2780-shEpoR cells were exposed to soluble EphB4, EphrinB2,
or EpoR. Soluble EpoR did not inhibit the interaction between
rhEpo and EphB4; however, soluble EphB4 and soluble
Figure 2. Characterization of rhEpo Binding to EphB4 Cells
(A) Analysis of competitive binding of [I125]rhEpo to A2780-parental, -shEpoR, -shEphB4, and shEpoR/shEphB4 cells.
(B) Kinetics of [I125]rhEpo binding to A2780-parental, -shEpoR, -shEphB4, and -shEpoR/shEphB4 cells.
(C) Analysis of competitive binding of [I125]rhEpo to EpoR WT and EpoR/ MEFs.
(D) Competitive binding studies using the EEL peptide in A2780-shEpoR or -shEphB4 cells.
(E) Proximity ligation assay using Cos-1EpoR, Cos-1EphB4, and mutated EphB4 cells. The scale bar represents 50 mm.
(F) The bar graph represents the quantification of ligation assay.
(G) Competitive binding studies using soluble EphB4, EpoR, or EphrinB2 in A2780-shEpoR cells. CPM, counts per minute. Mean ± SEM values are shown (n = 3).
See also Figure S2 and Tables S1 and S2.
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EphrinB2 blocked this interaction (Figure 2G). In A2780-
shEphB4 cells, soluble EpoR competitively inhibited rhEpo bind-
ing to EpoR, but soluble EphB4 and soluble EphrinB2 did not
block the interaction between rhEpo and EpoR (Figure S2M).
To test the specificity of competitive inhibition, we performed as-
says using IL3 (known to form heterodimers with EpoR [Krosl
et al., 1996]) and CXCL12 (unrelated to EpoR), and no inhibition
was noted (Figure S2N).
Epo-Mediated EphB4 Activation and Signaling
Serum rhEpo levels of 1–200 IU/ml in individuals given rhEpo
have been reported (McMahon et al., 1990; Olsson-Gisleskog
et al., 2007), but no data regarding levels in the tumor microenvi-
ronment were found. Thus, we evaluated human andmurine Epo
levels in A2780 tumors from mice treated with rhEpo (Figures
S3A–S3D). Hemoglobin levels increased with rhEpo treatment,
but there were no effects on white blood cells or platelet counts
(Figure S3E). On the basis of these data, we used 1–50 IU/ml
rhEpo for subsequent in vitro experiments. To test whether
rhEpo activates EphB4, we exposed A2780, SKOV3ip1, and
MDA-MB231 cells to rhEpo. Epo and EphB4 bind to each other
in a sustainedmanner (Figure S3F), leading to phosphorylation of
EphB4 (Figures 3A and S3G). To address whether cross-activa-
tion between EpoR and EphB4 could occur upon rhEpo stimula-
tion, we immunoprecipitated EpoR and probed for EphB4 in
A2780 parental cells, but no direct interaction was detected (Fig-
ure S3H). EPHB4 mRNA levels showed modest changes in cell-
cycle phases in two out of four cell lines tested. To further
confirm this, A2780 and MDA-MB231 cells were labeled with
EphB4 antibody and fluorescence-activated cell sorting sorted
according to cell cycle. Our data show that there was no signif-
icant change in EphB4 protein expression during different
phases of the cell cycle (Figure S3I).
As expected, rhEpo stimulation of A2780-shEphB4 cells, but
not A2780-shEpoR cells, resulted in activation of the Jak2/
STAT5 pathway (Figure 3B). In contrast, rhEpo stimulation of
A2780-shEpoR, but not A2780-shEphB4, cells resulted in
STAT3 activation (Figures 3B and S3J). To further exclude the
possible effect of EpoR in these experiments, we used EpoR/
MEFs, which are EphB4 positive (Figure S3K). We stimulated
the EpoR/ MEFs with rhEpo, and this resulted in increased
pSTAT3andpSrc levels (Figure3C).Similarly, EphrinB2 treatment
also resulted in STAT3 and Src phosphorylation (Figure S3L).
Immunoprecipitation (IP) of EphB4 followed by immunoblotting
(IB) for STAT3 revealed no evidence of direct binding between
these proteins (data not shown). We then evaluated Src as a
possible mediator between EphB4 and STAT3. Src IP followed
by EphB4 IB revealed the binding of these two proteins in
A2780-shEpoR cells after rhEpo stimulation (Figure 3D). There
wasnobindingbetweenEphB4andJak2. InA2780-shEpoRcells,
PP2 (Src inhibitor), but notPP3 (inactive), treatment resulted in the
blockage of rhEpo-induced STAT3 activation (Figure 3E). Similar
results were notedwith Src small interferingRNA (siRNA) (Figures
3E and S3M). To determine whether activated STAT3 binds to
DNA upon exposure to rhEpo, we used a consensus oligonucle-
otide containing a binding site for STAT3. rhEpo-treated A2780-
shEpoR, but not the -shEphB4, cells had >3-fold increase in
nuclear STAT3 levels compared to untreated cells (Figure 3F).
To further document the functionality of cellular EphB4, A2780-614 Cancer Cell 28, 610–622, November 9, 2015 ª2015 Elsevier Inc.shEpoR cells were exposed to EphrinB2-Fc, which resulted in
EphB4,Crk/Abl, andAktphosphorylation (FigureS3N).We further
confirmed this result in the EpoR/ MEFs (Figure S3O).
rhEpo Induces EphB4-Mediated Functional Effects
In Vitro
Exposure to rhEpo resulted in a significant increase in prolifera-
tion, migration, and invasion of the A2780 parental and -shEpoR
cells, but not of A2780-shEphB4 cells (Figures 4A–4C and S4A–
S4C). Given the activation of STAT3 signaling in response to
rhEpo in A2780-shEpoR cells, we examined the effects of
STAT3 silencing on these cells (Figure S4D). STAT3 siRNA
blocked Epo-induced proliferation (Figure S4E), migration, and
invasion of A2780-shEpoR cells (Figure 4D). EphrinB2 also
increased invasion, migration, and proliferation of the A2780
parental and -shEpoR cells, but not of the -shEphB4 cells (Fig-
ures S4F and S4G); these effects were disrupted by STAT3 or
Src siRNA (Figure S4H). EphrinB2 levels are not increased in
response to rhEpo treatment (Figure S4I). Similar effects of
rhEpo were noted in the MCF7 breast cancer cells using EpoR
or EphB4-targeted siRNA (Figure S4J). Moreover, rhEpo
increased proliferation, migration, and invasion of Cos-1 cells
transfected with EphB4. These effects did not occur in Cos-1
cells expressing EpoR or mutated EphB4 (Figures S4K–S4M).
rhEpo Induces EphB4-Mediated Biological Effects
In Vivo
Significant increases in tumor growth following rhEpo treatment
(Figures 5A and S5A) were noted in the SKOV3ip1, A2780, and
HeyA8 ovarian cancer mouse models. Using fluorescently
labeled (Alexa Flour 555) rhEpo, we confirmed the accumulation
of rhEpo in tumors (Figure S5B). rhEpo administration increased
the level of EphB4 phosphorylation in tumors (Figure S5C). Addi-
tional experiments revealed that rhEpo stimulated in vivo growth
of A2780-shControl and -shEpoR cells, but not of -shEphB4
or -shEpoR/shEphB4 cells (Figure S5D). Given the limitations of
shRNA for therapeutic applications, we also used siRNA pack-
aged in dioleoylphosphatidylcholine (DOPC) nanoliposomes for
systemic siRNA delivery to tumors (Ahmed et al., 2010; Halder
et al., 2005; Merritt et al., 2008a). rhEpo treatment increased tu-
mor growth in the A2780 tumors treatedwith DOPCalone or con-
trol siRNA-DOPC treatment groups (Figure S5E). While EpoR
siRNA-DOPC had no effect on rhEpo-stimulated tumor growth,
EphB4 siRNA-DOPC or combined EphB4/EpoR siRNA-DOPC
completely abrogated rhEpo-induced tumor growth (Figures
5B, S5F, and S5G). To exclude potential off-target effects, we
tested three additional EphB4 siRNA sequences. All three
sequences inhibited rhEpo-induced tumor growth in the A2780
model in vivo (Figure S5H). Moreover, Cos-1 cells, which do not
express EpoR or EphB4, were transfected with either wild-type
(WT) EphB4 or a mutated EphB4 plasmid carrying a non-sense
mutation at the EphB4 siRNA target site. Cells transfected with
WT EphB4 exhibited decreased EphB4 expression following
EphB4 siRNA transfection, whereas cells with mutated EphB4
had no change in EPHB4 expression (Figure S5I). Consistent
with in vitro findings, STAT3 siRNA-DOPC also blocked rhEpo
stimulated growth in the A2780-shEpoR model (Figure S5J).
Similar effects were noted with the MDA-MB231 (ER-negative;
Figure 5C) and MCF-7 (ER-positive; Figure S5K) breast cancer
(legend on next page)
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Figure 4. An Essential Role of EphB4 in
rhEpo-Mediated Effects on Cancer Cells
(A) Effect of rhEpo on proliferation at indicated
dosage.
(B and C) Proliferation (B), migration, and invasion
of A2780, -shEpoR, and -shEphB4 cells after
rhEpo treatment (C).
(D) Effect of STAT3 silencing on migration and in-
vasion in A2780-shEpoR cells. Mean ± SEM values
are shown. *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. n = 3.
See also Figure S4.models. Moreoever, in the RMG2 ovarian cancer model (EpoR+/
EphB4), rhEpo had no significant effect on tumor growth (Fig-
ure S5L). Next, we ectopically expressed WT EphB4 or the
mutated form of EphB4 that does not bind to Epo in the RMG2
(EphrinB2-negative) cells; while rhEpo stimulated the growth
of RMG2-EphB4 tumors (WT), it had no effect on the RMG2-
EphB4-mutated model (Figures 5D and S5M). Protein assess-
ment of A2780 tumors harvested at the end of the experiment
revealed >90% EpoR or EphB4 gene silencing in the respective
groups (Figure S5N). Effects of EpoR or EphB4 silencing on
downstream signaling were also found to be consistent with the
aforementioned in vitro findings (Figure S5N).Figure 3. Epo Binding to EphB4 Activates the Src-STAT Pathway
(A) Activation of EphB4 by rhEpo in A2780-parental cells.
(B) Evaluation of pJak-2, pSTAT5, and pSTAT3 levels (ELISA and western blot) following rhEpo treatment in
(C) Evaluation of pSTAT3 levels following rhEpo treatment in EpoR/ MEFs.
(D) Effect of rhEpo on EphB4 binding to Jak-2 and Src in A2780-EpoR cells.
(E) Effect of Src inhibitor (PP2, 10 mM; inactive counterpart, PP3) or Src siRNA on pSTAT3 levels following tr
relative fluorescence units); n = 3.
(F) Effect of rhEpo on STAT3 binding to a oligonucleotide containing consensus STAT3 binding site in A2780-s
for these experiments was 50 IU/ml. Mean ± SEM values are shown. *p < 0.05; ***p < 0.001.
See also Figure S3.
616 Cancer Cell 28, 610–622, November 9, 2015 ª2015 Elsevier Inc.To determine the effect of rhEpo on
cancer cell invasion in vivo, we analyzed
H&E sections from rhEpo-treated
A2780-shEpoR tumors. These results
show that rhEpo administration led to a
more invasive phenotype characterized
by infiltration of tumor deeply through
the muscle layers, while tumors in un-
treatedmice remained encapsulated (Fig-
ures S5O and S5P).
Next, we used the SKOV3ip1 (Eph-
rinB2-negative) model to examine poten-
tial effects of endogenous EphrinB2 on
murine cells. For this experiment, we
used RGD-labeled chitosan (CH) nano-
particles that are highly efficient for tar-
geted siRNA delivery (Han et al., 2008;
Pradeep et al., 2014; Rupaimoole et al.,
2014; Wu et al., 2014). Tumor-bearing an-
imals were randomized to (1) control
siRNA or (2) human EpoR siRNA (hEpoR
siRNA) and mouse EphrinB2 siRNA
(mEphrinB2 siRNA). rhEpo stimulated tu-mor growth in both groups (Figure S5Q and S5R). To exclude
the potential effects of murine EphrinB2 on EphB4 receptor in
tumor cells, we performed an additional experiment in which ID8-
VEGF (EphrinB2/EpoR/EphB4+) cellswere injected intraperito-
neally (i.p.) into EphrinB2KOmice (Figures 5E, S5S, andS5T).We
found that rhEpo still promotes tumor growth in this model.
EphB4 Expression Correlates with Clinical Outcome in
ESA-Treated Patients
Next, we addressed potential effects of tumoral EpoR or EphB4
expression on the effects of ESA treatment in patients with
ovarian (n = 175) or breast (n = 88) cancer (Figures 6A–6D andA2780, -shEpoR, and -shEphB4 cells.
eatment with rhEpo in A2780-shEpoR cells (RFUs,
hEpoR and -shEphB4 cells. The dose of rhEpo used
Figure 5. EphB4 Plays a Key Role in Epo-
Induced Tumor Growth In Vivo
(A) Effect of rhEpo (50 IU given 33/week i.p.;
n = 10) on tumor growth (aggregate tumor weight
after 3–5 weeks of rhEpo treatment) in orthotopic
ovarian cancer models in vivo.
(B) Effect of EphB4 and EpoR silencing on
SKOV3ip1 and A2780 tumor growth in vivo with or
without rhEpo treatment (n = 10).
(C) Effect of EphB4 or EpoR silencing on the
MDA-231 tumor growth in vivo with or without
rhEpo treatment (n = 10).
(D) Effect of ectopically expressed EphB4 or
EphB4 mutant on RMG2 tumor growth in vivo with
or without rhEpo treatment (n = 10).
(E) Effect of rhEpo (50 IU given 33/week i.p.;
n = 10) on ID8-VEGF tumor growth (aggregate tu-
mor weight after 3–5 weeks of rhEpo treatment;
1 3 106 ID8-VEGF murine ovarian cancer cells
were injected into EphrinB2/mice). Mean ± SEM
values are shown. **p < 0.01; ***p < 0.001.
See also Figure S5.S6A–S6C). EphB4 and EpoR protein levels were significantly
correlated with mRNA expression levels (Figures S6D and
S6E). The mean age of the patients with epithelial ovarian cancer
was 58.2 years (range, 20–92 years); 85% had serous histology,
and 91% had high-grade tumors. All patients were primarily
treated with combination platinum and taxane chemotherapy.
EpoR and EphB4 overexpression was detected in 79% and
39% of epithelial ovarian cancer samples, respectively (Table
S3). The disease-specific survival (DSS) in patients with high
EphB4-expressing tumors was significantly shorter than for pa-
tients with low EphB4-expressing tumors (p < 0.001; Figure 6E;
Table S4). DSS did not differ by level of EpoR expression (Fig-
ure 6F; p = 0.64; Table S4). In multivariate analysis, EphB4, but
not EpoR, overexpression was an independent predictor of
poor survival (Table S4). A high level of EphB4, but not EpoR,
expression was associated with shorter overall patient survival
compared to low EphB4 expression (p < 0.001; Figure 6G).Cancer Cell 28, 610–622,Next, we addressed the potential
impact of ESA-based treatment on sur-
vival of patients with ovarian cancer.
ESA-based treatment was associated
with shorter survival in patients with
EphB4-overexpressing tumors (2.18
versus 4.52 years; p = 0.0004), but not in
patients with low EphB4-expressing tu-
mors (4.38 versus 5.28 years; p = 0.19;
Figure 6H). To determine if EphB4 inter-
acts with ESA-based treatment to
adversely impact outcomes, a Cox pro-
portional hazards model was created
(Table S4). In this model, patients with
high EphB4 expression and ESA treat-
ment had increased risk of disease-
specific mortality than those with low
EphB4 and no ESA therapy (HR 5.66
[95% CI 3.11–10.31], p < 0.0001). In
contrast, patients with low EphB4 andESA therapy did not demonstrate a similar relationship (HR
0.88 (95% CI 0.45-1.74), p = 0.71). ESA therapy was associated
with worse survival in patients with low EpoR expression (p =
0.03; Figure S6F). To determine the specificity of the ESA and
EphB4 interaction, a parallel analysis was performed with
IL6rb, one of the other candidates identified in the in silico
screen; there was no impact on patient survival based on IL6rb
expression (Figures S6G–S6I).
To determine whether EphB4 expression is predictive of
outcome in patients with other malignancies, we also tested
breast cancer samples (n = 88; further details included in Tables
S5 and S6). DSS of ESA-treated breast cancer patients was
significantly lower compared to untreated patients (Figure 6I).
ESA-treated breast cancer patients with high EphB4 expression
showed significantly lower survival compared to untreated pa-
tients (Figure 6J). For those with available Her2 and estrogen
receptor status, ESA treatment was associated with increasedNovember 9, 2015 ª2015 Elsevier Inc. 617
Figure 6. Clinical Relevance of EphB4 and
EpoR Expression and ESA Treatment in
Cancer Patients
(A–D) Representative immunohistochemical
peroxidase staining for (A) EphB4 and (B) EpoR
expression in ovarian cancer and (C) EphB4 and
(D) EpoR expression in breast cancer samples.
(E–G) Kaplan-Meier curves of disease-specific
mortality for ovarian (E–H) and breast (I and J)
cancer patients stratified by tumoral expression of
(E) EphB4, (F) EpoR, or (G) both EphB4 and EpoR.
(H) Evaluation of disease-specific survival duration
of ovarian cancer patients based on ESA treatment
and EphB4 expression.
(I) Disease-specific survival analysis of breast
cancer patients stratified by ESA treatment.
(J) Disease-specific survival of breast cancer
patients based on ESA treatment and EphB4
expression. The scale bar represents 50 mm.
See also Figure S6 and Tables S3, S4, and S5–S7.risk of death (HR: 4.09; 95% CI = 1.32–12.68). After stratifying
patients according to receptor status, those with Her2-negative
tumors had an increased risk of death with ESA therapy (HR:
10.3; 95% CI = 1.07–98.76; Table S7). Collectively, we propose
a model whereby Epo interacts with the EphB4 receptor, leading
to downstream Src and STAT3 activation (Figure 7).
DISCUSSION
This study identified EphB4 as a previously unrecognized Epo re-
ceptor that is responsible for the deleterious effects of exoge-
nous Epo administration on the survival of cancer patients. The
computational, biochemical, molecular, cellular, animal, and
clinical data support the role of EphB4 as a functional Epo
receptor.618 Cancer Cell 28, 610–622, November 9, 2015 ª2015 Elsevier Inc.Administration of exogenous Epo in
patients with cancer has been linked
with tumor progression (Crouch and De-
Santis, 2009; Kumar et al., 2012; To´va´ri
et al., 2008; Wang et al., 2011), but the
mechanism remained elusive until now.
Although the interaction between Epo
and the canonical EpoR can explain tu-
mor progression in some models,
mounting evidence indicates that this
interaction is not involved in most Epo-
induced tumor growth (Sturm et al.,
2010; Kassem and Yassin, 2010). A
possible explanation to this puzzle is the
concept that alternative EpoRs (e.g.,
EpoR-IL3 heterodimer and soluble
EpoR) can account for non-hematological
effects, but these alternative receptors
have not explained Epo-induced tumor
progression. Our results have broad im-
plications for understanding Epo biology.
For example, the Epo-EphB4 pathway
could potentially explain some of thenon-hematologic functions of Epo. EphB4 is present and tends
to colocalize with EpoR in a subset of cortical neurons (Fig-
ure S6J) (Uhle´n et al., 2015). Pharmacological doses of cEpo
have neuroprotective effects that have been shown to be inde-
pendent of EpoR function (Sturm et al., 2010). Epo has been
shown to prevent chemotherapy-induced neurotoxicity in can-
cer patients (Kassem and Yassin, 2010). Administration of Epo
after a stroke can reduce the extent of damage and accelerate
patient recovery (Chang et al., 2005; Noguchi et al., 2007).
EphB4 appears to be a low-affinity receptor for rhEpo based
on the biochemical data. The concentration of rhEpo used
for the biological experiments (50 IU/ml) corresponds to 10–
15 nM, which is 1% to 2% of the KD value (KD = 881 nM) for
the binding of rhEpo to EphB4, as measured in the MST assay.
These data suggest that as a relatively low-affinity binding event,
Figure 7. Proposed Model of Epo-Mediated
EphB4 Signaling in Cancer Cellsinteraction between rhEpo and EphB4 is a pharmacologically
efficient process. Other ligand-receptor systems that display
similar phenomena have been reported previously (Authier and
Desbuquois, 2008; Hutchinson et al., 2003; Mason and Tager,
1985). Whether EphB4 exists as a dimer in cancer cells is not
known and will require additional work. Our findings can also
be extrapolated to the mechanism by which Epo could poten-
tially induce neovascularization in normal organs (Davies et al.,
2009; Salvucci et al., 2006), a process also regulated by EphB4.
The discovery of EphB4 as an alternative Epo receptor has
multiple clinical implications including opportunities for patient
stratification and anti-EphB4 approaches to abrogate the stimu-
latory effects of Epo on tumor growth. In summary, Epo-EphB4
interactions on tumor cells provide a previously unrecognized di-
mernsion for our understanding of Epo-mediated tumor growth.
EXPERIMENTAL PROCEDURES
Animal Model Studies
Female athymic nude mice (NCr-nu) and immunocompetent (C57BL/6) mice
(5–8 weeks) were purchased from the NCI-Frederick Cancer Research and
Development Center. B6;129S-Eportm1Liz/J and B6.129S7-Efnb2tm2And/J
mice were purchased from Jackson Laboratory and maintained as previously
described (Merritt et al., 2008b; Thaker et al., 2006). All animal work was per-
formed in accordance with protocols approved by the MD Anderson Institu-
tional Animal Care and Use Committee. Mice were cared for in accordance
with the guidelines set forth by the American Association for Accreditation of
Laboratory Animal Care and the U.S. Public Health Service Policy on Human
Care and Use of Laboratory Animals.
MST
MST experiments were performed using a NanoTemper NT.115 Monolith sys-
tem (Jerabek-Willemsen et al., 2011). Temperature wasmaintained at 25C for
all experiments. Purified, recombinant proteins were obtained from Cell Sci-
ences (epoetin) and Sino Biological (EpoR, EphB4, and EphrinB2/Fc). Fluores-
cence labeling of rhEpo and EphB4 was achieved through primary amide
coupling with NT-647 dye (NanoTemper), and labeled protein was purified
from free dye using Sephadex G25 resin (GE Healthcare). The concentration
of NT-647-labeled protein was maintained at 25 nM throughout, and titration
series of unlabeled protein were accomplished with dilution in assay bufferCancer Cell 28, 610–622,(10 mM HEPES [pH 7.5], 150 mM NaCl, 0.5 mM
TCEP, and 0.05% Tween-20). Individual samples
were made to %5 ml in standard glass capillaries
(NanoTemper). A thermal gradient of 3C pro-
duced the characteristic thermophoretic trace for
each sample. Each data point represents the
average of triplicate repeats, and the reported error
is the SD of triplicate repeats. Data were analyzed
using NanoTemper software. Affinities calculated
near the concentration of labeled protein (25 nM)
are denoted KD,app as a higher inherent error is
expected.
SPR: Immobilization of EphB4 Receptor to
Sensor Chip
The stock solution (100 mg/ml) of EphB4 in PBS
was diluted to 25 mg/ml with 10 mM sodium ace-
tate buffer at pH 4.5 and immobilized to a CM5
sensor chip using the amine-coupling reaction
following manufacturer-provided procedures(BIACORE). Briefly, the surfaces of the chips in flow cells (FC)-1, -2 were acti-
vated by exposing them to a mixture of 200 mM N-ethyl-N’-dimethylamino-
propyl carbodiimide and 50 mM N-hydroxysuccinimide for 7 min. FC-1 was
used as a reference surface andwas directly deactivated by injecting 1Metha-
nolamine at pH 8.5 for 7 min. FC-2 was injected with 25 mg/ml EphB4, followed
by injection of 1 M ethanolamine to block the remaining activated ester groups
on the surface. The chip was allowed to stabilize for at least 2 hr in HBSEP
running buffer before injecting test analytes. The experiments were performed
in triplicate.
SPR Binding Assays between EphrinB2 and EphB4
Binding assays were performed in triplicate at 25C in HBSEP running buffer.
EphrinB2 was diluted in HBSEP buffer, filtered, degassed, and injected at
concentrations between 0.6 and 40 nM at a flow rate of 30 ml/min. The injection
time of EphrinB2 into the HBSEP buffer was 7 min, followed by a 3-min disso-
ciation period. The chips were regenerated using a 30-s pulse of 10 mM
glycine (pH 2.2) after each binding circle. Each cycle consisted of a 2-min
waiting period to allow for monitoring of the baseline binding stability. For sub-
traction of bulk effects, caused by changes in the buffer composition or
nonspecific binding, we performed double referencing. Therefore, all analyzed
samples were additionally injected onto an uncoated reference surface,
including a sample of the running buffer, which was also tested on the
EphB4 coated flow cell.
Competition of rhEpo and EphrinB2 for the EphB4 Receptor
The ability of rhEpo to inhibit EphrinB2 binding to EphB4 was assessed in a
competitive binding assay. Serial dilutions of rhEpo from 0.39 to 100 nM
were mixed with a predetermined concentration of EphrinB2 (2.5 nM) in
HBSEP buffer containing 0.1 mg/ml BSA to prevent nonspecific binding. The
mixture was injected at a flow rate of 30 ml/min over an EphB4-coated flow
cell, as well as over a control flow cell. After each injection, the signal from
the control flow cell was subtracted, and then the relative amount of protein
bound to EphB4 was recorded as the net response over pre-injection baseline.
Regenerationwas achievedwith a 30-s pulse of 10mMglycine (pH 2.2). Bound
protein shown as response units (RU) was plotted as a function of Epo concen-
tration and fit to a three-parameter non-linear regression using GraphPad
Prism 5.0.
The ability of rhEpo binding to other Eph receptors was tested by competi-
tive binding assay. To test this, tubes were coated with 100 ml of EphA2
(100 nM), EphA3 (100 nM), and EphB2 (100 nM) at 4C. Serial dilutions of
EphrinA1, EphrinA2, and EphrinB2 from 0.01 to 100 nMwere mixed with a pre-
determined concentration of [I125] rhEpo (10 nM) in HBSEP buffer containing
0.1 mg/ml BSA to prevent nonspecific binding. Radioactivity (signal) wasNovember 9, 2015 ª2015 Elsevier Inc. 619
measured after 2 hr of incubation. The data are expressed as a percent of bind-
ing. The experiments were performed in triplicates.
Immobilization ofMonoclonalMouse Anti-human IgG-Fc Antibody to
Sensor Chip, and Analysis of Binding between Epo and rhEpoR-Fc
The same procedure as described before was performed to coat the mono-
clonal mouse anti-human IgG (Fc) antibody (Biacore, BR-1008-39) on a CM5
chip, which was ready for capture analysis. In capture analysis, each cycle
consisted of (1) capture of rhEpoR-Fc by injection of 500 ml rhEpoR-Fc over
flow cell 2, (2) 1-min stabilization time, (3) 60-ml injection of Epo (concentration
range of 13.4 to 107 nM in 2-fold dilution increments) over flow cells 1 and 2
with flow cell 1 as the reference flow cell, (4) 5-min dissociation (buffer flow),
(5) regeneration of anti-human IgG surface with a 120-s injection of 3 M
MgCl2 at 50 ml/min, and (6) 1-min stabilization time before the start of next cy-
cle. The signal wasmonitored as flow cell 2 minus flow cell 1. All samples and a
buffer blank were injected in duplicate.
Clinical Samples
Data and paraffin-embedded tissue samples on 175 consecutive patients with
ovarian cancer and 88 consecutive patients with breast cancer were obtained
following Institutional Review Board approval at MD Anderson and University
of Puerto Rico, as well as informed consent. There were no significant differ-
ences in patient demographics, clinical stage, or known prognostic factors
for either cohort of patients. All patients in the ovarian cancer cohort were
treated with a combination of surgical cytoreduction, followed by adjuvant tax-
ane and platinum chemotherapy. Clinical samples were scored for staining
with the EphB4, EpoR, and IL6rb antibodies by a board-certified pathologist
who was blinded to the clinical outcome of the patients. EphB4, EpoR,
and IL-6rb expression was determined semiquantitatively by assessing the
distribution of the positive cells and the staining intensity in the tumor cells,
as previously described (Lu et al., 2010; Merritt et al., 2008a). An overall
H-score >100 was defined as high expression and %100 was defined as
low expression, according to the method described by McCarty et al.
(1985), who consider both the intensity of staining and the percentage of cells
stained in their approach. The expression of EpoR and EphB4was also verified
by qRT-PCR in selected patients. To test for a difference in survival by EphB4
expression, we used 175 patients with 60% in the first group (low expression)
and specified the median survival time of 6.7 years in low expressers and
3 years in high expressers of EphB4. We thereby expected 65 deaths among
low expressers and 42 deaths among high expressers and consequently had
99% power to detect the observed difference in survival curves. A similar post
hoc power analysis was performed in the breast cohort, and we had 70% po-
wer to detect the observed difference in survival curves.
Statistical Analysis
Fisher’s exact test was used to examine associations between EphB4, EpoR,
and IL6rb expression and ESA treatment in human samples and clinical vari-
ables. Kaplan-Meier survival curves and log rank tests were used to examine
the association between tumor expression of EphB4, EpoR, or IL6rb and pa-
tient disease-specific survival with and without ESA treatment. Multivariable
analysis was performed using the Cox proportional hazards model. The data
for this analysis were tested (plot of differences in log of cumulative hazard
rates of test variable against time) and found to conform to the proportional
hazards assumptions. For animal experiments, ten mice were assigned to
each treatment group. This sample size gave 80% power to detect a 50%
reduction in tumor weight with 95% confidence. Mouse and tumor weights
and the number of tumor nodules in each group were compared. Data are pre-
sented as mean ± SD. Statistical comparisons between experimental groups
were analyzed by unpaired Student’s t test, and a two-tailed p < 0.05 was
taken to indicate statistical significance. For analyzing the correlation, we
used Pearson’s test and the p values are indicated. We also used Mann-Whit-
ney rank sum test as indicated. All statistical tests are two-sided. For in vitro
studies, those with continuous variables were compared using the student
t test if normally distributed. Differences in variables that were not normally
distributed were compared using a nonparametric test (Mann-Whitney
U test). Again, a p value less than 0.05 is deemed statistically significant. All
statistical tests are two-sided. Only two-tailed values are reported in this study.
The full experimental procedures are described in the Supplemental Exper-
imental Procedures.620 Cancer Cell 28, 610–622, November 9, 2015 ª2015 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2015.09.008.
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